RxDoctor Payments Data

Christian Cyr, NP

Acute Care · Yuma, AZNPI 1871086249

Payments from drug & device makers

$2,255in general payments, 2019–2025

Across 21 payments — averaging $107.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$701
  • Amgen$676
  • Abbott$361
  • Baxter Healthcare$197
  • Bayer$124
  • AbbVie$115
  • plus $81 from 1 others

What the payments were for

  • Food & beverage$2,255100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca6$701
Amgen7$676
Abbott3$361
Baxter Healthcare2$197
Bayer1$124
AbbVie1$115
GSK1$81

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,255 in reported general payments places this provider in the 75th percentile of 482 acute care providers in Arizona.

See all acute care providers in Arizona

Medicare billing

Part B allowed, 2024
$2,787,839
Medicare patients
631
Services billed
246,081

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol71$94,103
LokelmaSodium Zirconium Cyclosilicate11$15,790
KerendiaFinerenone12$13,564
Calcitriol88$2,145
Calcium Acetate15$1,488
Potassium Citrate ErPotassium Citrate11$1,067
Tamsulosin Hcl38$871
Losartan Potassium68$721
Metoprolol Succinate29$692
Metolazone28$677
Oxybutynin Chloride ErOxybutynin Chloride14$645
Glipizide ErGlipizide16$612
Amlodipine Besylate52$498
Finasteride25$494
Potassium Chloride26$468

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$701$109,89382 claims
BayerKerendia$124$13,56412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 482 acute care providers in Arizona.

Other acute care in Yuma

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →